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Andrzej Budaj, MD, PHDSEE PAGE 59I t is well-recognized that bleeding during hospi-talization for acute coronary syndrome (ACS) orfollowing percutaneous coronary intervention
is associated with an increased risk of subsequent
adverse outcomes, including death, myocardial in-
farction (MI), stroke, and stent thrombosis (1–3).
Therefore, bleeding prevention is now recognized as
just as important a goal as prevention of ischemic
events. Risk stratiﬁcation for in-hospital bleeding
and antihemorrhagic management is a Class I re-
commendation in the guidelines (4,5). Despite the
availability of standardized deﬁnitions of bleeding,
developed by the Bleeding Academic Research
Consortium (BARC), various deﬁnitions have been
used in clinical trials to assess bleeding for both in-
hospital and post-discharge periods. BARC deﬁnitions
have been well-validated and are particularly suited
for assessment of post-discharge bleeding, enabling
collection of patient reports (6–8). However, most
studies showing associations between bleeding and
outcomes have focused on major bleeding events.
Even in those reports demonstrating an impact of mi-
nor bleeding on outcomes, the deﬁnitions of minor
bleeding would be classiﬁed as greater than BARC
type 2 (3). The BARC deﬁnition enables the identiﬁca-
tion of clinically very minor bleeding, BARC type 1,
that does not require medical care or hospitalization.
Although the impact of bleeding on clinical out-
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Editor for this paper.of life (QOL) after ACS are scarce. The latter is of
particular interest in the context of recommendations
for prolonged dual antiplatelet therapy (DAPT) with
more potent P2Y12 inhibitors (4,9). In this issue of the
Journal, Amin et al. (10) analyze the prevalence and
impact of bleeding on QOL and health utilities in
9,290 acute MI patients in the TRANSLATE-ACS
(Treatment with ADP Receptor Inhibitors: Longitudi-
nal Assessment of Treatment Patterns and Events
after Acute Coronary Syndrome) registry treated with
percutaneous coronary intervention and discharged
on DAPT. The primary outcome was the 6-month EQ-
5D (a standard 5-question QOL tool) index score and
secondary EQ-5D visual analog scale (VAS), also at 6
months. The magnitude of difference in QOL was
estimated by using Cohen’s d index. The entire
spectrum of post-discharge BARC bleeding types was
analyzed, and the following comparisons were made:
none versus any bleeding, BARC type 1, BARC type 2
to 4, and BARC type 3 to 4.The investigators demonstrated a high prevalence
of any BARC bleeding (24.2%) and its association with
worse 6-month health-state utilities and QOL. The
degree of impairment increased in a stepwise fashion
with bleeding severity. However, the follow-up
period of 6 months in the study was relatively short.
In contrast, recent evidence demonstrated an
ischemic beneﬁt associated with prolonged DAPT for
2 to 3 years following the occurrence of an acute
coronary event. Therefore, we deﬁnitely need better
identiﬁcation of bleeding risk to maximize the risk/
beneﬁt ratio given that therapy with prolonged DAPT
has also been associated with a deﬁnite increased risk
of severe bleeding compared with aspirin mono-
therapy. The increased use of prolonged DAPT in
clinical practice, even in patients with high ischemic
and low bleeding risk, will likely increase the inci-
dence of bleeding. In the current registry, most pa-
tients were treated with clopidogrel (68%). However,
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P2Y12 inhibitors than clopidogrel along with the evi-
dence of anti-ischemic beneﬁts from prolonged DAPT
will affect bleeding incidence with resulting conse-
quences of decreased QOL.
Amin et al. (10) applied contemporary tools for
estimating QOL and health status. The EQ-5D index
score, based on the U.S. population preferenceweights
validated for ACS, examined various QOL domains:
mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression. QOL was also assessed with
the EQ-5D VAS to self-estimate overall health status of
each patient. Importantly, BARC bleeding was inde-
pendently associated with EQ-5D index score and a
lower QOL according to the VAS at 6 months. Both
scores declined in a stepwise fashion with increasing
BARC bleeding severity. The decrement in EQ-5D and
Cohen’s d index were similar to the effect sizes
observed for cancers. Therefore, the decrease in QOL
associated with bleeding was clinically meaningful.
The current study enabled the assessment of very
minor (close to nuisance) BARC type 1 bleeding,
deﬁned as “bleeding that does not cause the patient
to seek medical care or hospitalization and is not
actionable.” In contrast to the harder endpoints of
BARC type 2 (hospitalization), BARC type 3 (hemo-
globin drop/transfusion), and BARC type 5 (fatality)
bleeding, identiﬁcation of BARC type 1 bleeding in
clinical trials will require more effort than chart re-
view. BARC 1 bleeding occurred in 9.1% of patients
during 6-month follow-up in the current study, and
there was a signiﬁcant independent association be-
tween BARC type 1 bleeding and decreased QOL
expressed by both scales. BARC type 1 bleeding
negatively inﬂuenced all EQ-5D QOL domains, none
of which are trivial endpoints.
In the TRIUMPH (Translational Research Investi-
gating Underlying Disparities in Acute Myocardial
Infarction) registry of 3,560 post-MI patients treated
with DAPT for 1 year, the same group of investigators
demonstrated that BARC type 1/nuisance bleeding was
common (37.5% during 12 months) and independentlyassociated with worse QOL (11). The latter high fre-
quency of BARC type 1 bleeding with more prolonged
therapy and its consequences should be taken into
consideration when making decisions regarding opti-
mization of DAPT duration. In earlier single-center
studies, investigators showed that nuisance bleeding
had a negative impact on antiplatelet therapy adher-
ence (12,13). The latter raises potential criticism for the
deﬁnition of BARC type 1 bleeding as “not actionable”
when, in fact, the patient may “take action” and dis-
continue medication without seeking medical atten-
tion. Self-discontinuation of DAPT places patients
at risk for recurrent ischemic events, including
stent thrombosis. BARC type 1 bleeding, although not
correlated with mortality, is clinically relevant.
Less severe forms of bleeding as reported by pa-
tients have not been rigorously collected and adjudi-
cated in current clinical trials. The clinical relevance of
this “low-grade” bleeding mandates recording these
bleeds, particularly in studies of new and more potent
antiplatelet and antithrombotic agents as well as in
studies investigating optimal duration of therapy.
Standardized surveys used to assess bleeding compli-
cations in patients with hematologic disorders may
facilitate identiﬁcation of speciﬁc signs of bleeding.
Less severe forms of bleeding should also be consid-
ered in clinical practice for individualizing decisions
regarding antiplatelet and anticoagulation therapy.
The current TRANSLATE-ACS registry analysis
holds important implications for clinical practice
and future clinical trials. It expanded the impact of
bleeding from clinical outcomes to QOL, documented
the usefulness of the entire spectrumof BARC bleeding
deﬁnitions, and encouraged more proactive assess-
ment of all bleeding, including the BARC type
1/nuisance-type bleeding.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Andrzej Budaj, Department of Cardiology, Gro-
chowski Hospital, Postgraduate Medical School,
Grenadierow 51/59, 04-073 Warsaw, Poland.
E-mail: abudaj@kkcmkp.pl.RE F E RENCE S1. Eikelboom JW, Mehta SR, Anand SS, et al.
Adverse impact of bleeding on prognosis in pa-
tients with acute coronary syndromes. Circulation
2006;114:774–82.
2. Rao SV, O’Grady K, Pieper K, et al. Impact of
bleeding severity on clinical outcomes among
patients with acute coronary syndromes. J Am Coll
Cardiol 2006;47:809–16.
3. Budaj A, Eikelboom JW, Mehta SR, et al.
Improving clinical outcomes by reducing bleedingin patients with non-ST-elevation acute coronary
syndromes. Eur Heart J 2009;30:655–61.
4. Rofﬁ M, Patrono C, Collet JP, et al. 2015 ESC
guidelines for the management of acute coronary
syndromes in patients presenting without persis-
tent ST-segment elevation: Task Force for the
Management of Acute Coronary Syndromes in
Patients Presenting Without Persistent ST-
Segment Elevation of the European Society of
Cardiology (ESC). Eur Heart J 2015 Aug 29 [E-pub
ahead of print].5. Levine GN, Bates ER, Blankenship JC, et al.
2011 ACCF/AHA/SCAI guideline for percutaneous
coronary intervention. A report of the American
College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines and
the Society for Cardiovascular Angiography
and Interventions. J Am Coll Cardiol 2011;58:
e44–122.
6. Mehran R, Rao SV, Bhatt DL, et al. Standardized
bleeding deﬁnitions for cardiovascular clinical
trials: a consensus report from the Bleeding
Budaj J A C C V O L . 6 7 , N O . 1 , 2 0 1 6
Consequences of Bleeding J A N U A R Y 5 / 1 2 , 2 0 1 6 : 6 6 – 8
68Academic Research Consortium. Circulation 2011;
123:2736–47.
7. Ndrepepa G, Schuster T, Hadamitzky M, et al.
Validation of the Bleeding Academic Research Con-
sortium deﬁnition of bleeding in patients with cor-
onary artery disease undergoing percutaneous
coronary intervention. Circulation 2012;125:1424–31.
8. Kikkert WJ, van Geloven N, van der Laan, et al.
The prognostic value of Bleeding Academic
Research Consortium (BARC)-deﬁned bleeding
complications in ST-elevation myocardial infarc-
tion: a comparison with the TIMI (Thrombolysis in
Myocardial Infarction), GUSTO (Global Utilization
of Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries) and ISTH (Inter-
national Society on Thrombosis and Haemostasis)bleeding classiﬁcations. J Am Coll Cardiol 2014;
63:1866–75.
9. Udell JA, Bonaca MP, Collet JP, et al. Long-
term dual antiplatelet therapy for secondary pre-
vention of cardiovascular events in the subgroup
of patients with previous myocardial infarction: a
collaborative meta-analysis of randomized trials.
Eur Heart J 2015 Aug 31 [E-pub ahead of print].
10. Amin AP, Wang TY, McCoy L, et al. Impact of
bleeding on quality of life in patients on DAPT:
insights from TRANSLATE-ACS. J Am Coll Cardiol
2016;67:59–65.
11. Amin AP, Buchuwar A, Reid KJ, et al. Nuisance
bleeding with prolonged dual antiplatelet ther-
apy after acute myocardial infarction and itsimpact on health status. J Am Coll Cardiol 2013;
61:2130–8.
12. Roy P, Bonello L, Torguson R, et al. Impact on
“nuisance” bleeding on clopidogrel compliance in
patients undergoing intracoronary drug eluting
stents implantation. Am J Cardiol 2008;102:1614–7.
13. Ben-Dor I, Torguson R, Scheinowitz M, et al.
Incidence, correlates, and clinical impact of nuisance
bleeding after antiplatelet therapy for patients with
drug eluting stents. Am Heart J 2010;159:871–5.
KEY WORDS acute coronary syndromes, BARC
(Bleeding Academic Research Consortium)
deﬁnitions, bleeding, DAPT (Dual Antiplatelet
Therapy), quality of life
